B6 Dosage: How Much Is Safe, and Where Harm Starts

Paid links: Some links in this article go to iHerb through an affiliate program: if you buy something after clicking one, StarterScience earns a commission and you pay the same price. That commission never changes how we describe the evidence, including when the evidence is weak. This article is general information, not medical advice — talk to a qualified healthcare professional before starting any supplement.

Searching for a B6 dose returns two very different kinds of number, and confusing them is how people get hurt by this vitamin. The first is what the body needs: 1.3 to 2.0 mg a day for adults. The second is where B6 stops being harmless — and here the US and European expert panels disagree by a factor of eight. The US tolerable upper intake level is 100 mg a day; the European one, revised in 2023, is 12 mg a day.

This article sets out where each of those numbers comes from, what the trials at high doses actually measured, where the documented harm starts, and which medicines and conditions change the answer.

The requirement is small, and most diets already cover it

The US Recommended Dietary Allowances come from the Institute of Medicine's 1998 review. They were set to keep plasma pyridoxal 5'-phosphate (PLP, the active form circulating in blood) at or above 20 nmol/L, assuming about 75% of the B6 in a mixed diet is absorbed.

The same review reported median B6 intake from food alone of roughly 2 mg/day for US men and 1.4 mg/day for US women, and noted that clinical signs of deficiency "have been observed only in controlled studies during depletion with very low levels of B6 and have never been seen at intakes of 0.5 mg/day or greater."

The honest complication: adequate intake on paper does not always mean adequate blood levels. The NIH Office of Dietary Supplements notes that "11% of vitamin B6 supplement users and 24% of people in the United States who do not take supplements containing vitamin B6 have low plasma PLP concentrations (less than 20 nmol/L)," and that in the 2003–2004 NHANES analysis some groups had low PLP even while consuming 2.0–2.9 mg/day. So B6 deficiency is not the common emergency the supplement aisle implies, but "everyone is fine" is not right either.

Why the ceiling is 100 mg in the US and 12 mg in Europe

Both ceilings are built on the same injury — sensory peripheral neuropathy, nerve damage that usually starts as numbness, tingling or burning in the feet and hands. They differ because the panels chose different anchor studies and different safety margins.

The disagreement is not about biology, it is about which weak human data to trust. The case–control study behind the European numbers (Dalton and Dalton, 1987) was rejected outright by the Institute of Medicine, whose own words were that "the weaknesses of this study and the inconsistency of the results with the weight of evidence pertaining to the safety of higher doses of pyridoxine rule out the use of these data to determine a UL." EFSA re-read the same study two decades later, added national vigilance reports that did not exist in 1998, and reached the opposite conclusion.

Two practical details of the 2023 EFSA opinion. First, the 12 mg "includes dietary and supplemental intake and covers all vitamin B6 vitamers" — it is a total, not an allowance on top of food, and it does not exempt pyridoxal 5'-phosphate (P-5-P) products. Second, the limits for younger people are far lower: EFSA sets 6.1–10.7 mg/day for ages 7–17, 3.2–4.5 mg/day for ages 1–6 and 2.2–2.5 mg/day for infants aged 4–11 months. The corresponding US limits are much higher (30 mg at 1–3 years, 60 mg at 9–13, 80 mg at 14–18), which is the same eight-fold argument repeated for children. EFSA applied the 12 mg to pregnancy and lactation as well, finding "no indication for a specific risk or increased susceptibility" but no reason to allow more.

What the high-dose trials found

If 50 and 100 mg products did nothing, nobody would sell them. Here is what happened when doses far above the RDA were actually tested. Note how thin most of these evidence bases are — and that the sturdiest findings are negative.

Read as a whole, the pattern is uncomfortable for the category. The largest and best-controlled evidence on B6 megadoses is evidence that they do not work: no effect on heart attacks, none on all-cause death, none on cognition, and a harm signal in male smokers for lung cancer. The positive results sit where trials are small, old or graded high risk of bias by the reviewers themselves. If you are comparing B6 products on the market, that is the realistic expectation to buy with.

Where the milligrams actually come from

EFSA surveyed the European market while writing the 2023 opinion, and the numbers are more interesting than the usual scare story. Across 2,145 supplements the labelled dose per serving ranged "from 0.02 up to 90 mg of vitamin B6", but the average was 3 mg and the median just 1.4 mg; only about 1.4% of products (29 of 2,145) declared more than 20 mg. Fortified products behaved similarly: sports and energy drinks 0.2–11.6 mg per serving (median 1.4 mg), breakfast cereals 0.06–3.2 mg (median 0.36 mg), nutritional drinks and other beverages 0.1–17 mg (median 0.7 mg).

So the typical stack is not the problem. A median supplement, a median energy drink and a median bowl of fortified cereal add up to roughly 3 mg a day — under both ceilings. The problem is the tail of that distribution, because the tail is not labelled as extreme: EFSA found single meal-replacement drinks at 14–17 mg per serving and one hot beverage marketed for PMS at 65 mg per serving. A single 17 mg serving already exceeds the European limit for the whole day. EFSA also reviewed a case report of neuropathy in a man drinking six energy drinks a day, each containing 5.1 mg — 31 mg/day, from no product that looked like a supplement at all.

US labels make the arithmetic easy. The FDA Daily Value for vitamin B6 is 1.7 mg, so any product listing a percentage in the thousands (a 50 mg tablet works out at roughly 2,900% DV) is a pharmacological dose regardless of the marketing. It is worth comparing the labelled milligrams across B6 products before buying, because the same shelf holds 1.4 mg and 90 mg versions of what is sold as the same thing.

The nerve damage that sets the limit

The syndrome was described in 1983 in the New England Journal of Medicine: seven adults with ataxia and severe sensory nerve dysfunction after daily high-dose pyridoxine, 2 to 6 grams a day for 2 to 40 months, mostly women treating premenstrual symptoms. Four were severely disabled and unable to walk; all improved after withdrawal.

Grams a day is easy to dismiss. What changed EFSA's assessment in 2023 was evidence far below that. The Dutch nutrivigilance system supplied 47 well-documented cases with doses, latency times and plasma PLP: supplemental doses ranged from 1.4 to 209 mg/day, and 41 of the 47 were at 100 mg/day or less. In the 12–21 mg/day band there were seven cases with latencies of three weeks, three months, eleven months, one year, five years, fifteen years and twenty years. France's system reported eight cases of neuropathy below the then-current 25 mg/day limit, "of which one at an intake of 21 mg/day with a latency period of 1 month with the causality judged to be likely." Finland reported adverse effects from 50 mg/day upward and no neuropathy cases below 25 mg/day. EFSA's conclusion was deliberately cautious: peripheral neuropathy "may occur at supplemental vitamin B6 intakes of 50 mg/day in some individuals," with large differences between individuals in susceptibility.

Two features of that data matter more than any single number. The dose–time relationship runs inversely — higher doses produce symptoms sooner — so a long run at a moderate dose is not automatically safer than a short run at a high one. And latency can be measured in years, which means the daily total sustained over time is the figure to watch, not the biggest number on any one label.

Symptoms worth acting on: numbness, pins and needles, burning or electric-shock sensations in the feet or hands, and unsteadiness when walking. If they appear while you are taking supplemental B6, stop and see a clinician rather than waiting it out.

Recovery is likely but not guaranteed, and the article you are reading should not pretend otherwise. In the case–control study EFSA used as its anchor, 55% of women reported partial or complete recovery three months after stopping and all had recovered by six months — but that study also recorded a woman whose neuropathy returned when she restarted B6 at 50 mg/day, and it is the same study the Institute of Medicine judged too unreliable to use. Against it sit the Dutch reports of people who had been taking modest doses for fifteen and twenty years before reporting nerve symptoms. Treat "it goes away when you stop" as a reasonable expectation, not a guarantee, and not as permission to keep taking a dose you are uneasy about.

Who genuinely may need more than the RDA

"More than the RDA" here means single-digit milligrams or a prescription, not a 100 mg habit.

• People with impaired kidney function. The NIH notes that people with end-stage renal disease and chronic renal insufficiency "often have low vitamin B6 concentrations," and that plasma PLP is also low in patients on maintenance dialysis or intermittent peritoneal dialysis and after kidney transplant.
• People with malabsorption or autoimmune disease. Low plasma PLP is common in celiac disease, Crohn's disease, ulcerative colitis and rheumatoid arthritis; in rheumatoid arthritis, concentrations fall as disease severity rises, and supplements normalise the vitamin without suppressing inflammatory markers.
• People with alcohol dependence. Plasma PLP "tend[s] to be very low," because acetaldehyde reduces net PLP formation and competes with PLP for protein binding.
• Women using combined oral contraceptives. In NHANES data on over 6,000 Americans, "most oral contraceptive users had plasma PLP < 20 nmol/L," and that analysis concluded intakes of 3 to 4.9 mg/day "appear consistent with the definition of a Recommended Dietary Allowance for most Americans." The Institute of Medicine's counterpoint is that the drop may reflect hormonal effects on tryptophan metabolism "rather than any deficiency of B6 per se." Both readings point to a few milligrams, not fifty.
• People taking isoniazid for tuberculosis. The FDA label states that "pyridoxine (vitamin B6) deficiency is sometimes observed in adults with high doses of isoniazid" and that "concomitant administration of pyridoxine (B6) is recommended in the malnourished and in those predisposed to neuropathy (e.g., alcoholics and diabetics)." The dose belongs to the prescriber.
• Adults over 50. The RDA itself rises, to 1.7 mg for men and 1.5 mg for women.

Everyone else is buying insurance rather than fixing a deficit. If that is the case, a low-dose B6 product performs the same as a high-dose one on every outcome the trials above measured.

Medicines that change the B6 equation

This list is not exhaustive, and interactions run in both directions — some drugs deplete B6, and B6 can blunt some drugs. Anyone on regular medication should check with a pharmacist before adding a standalone B6 supplement, which delivers far more than the trace amount inside a multivitamin.

• Levodopa without carbidopa. The carbidopa–levodopa label is explicit: "Pyridoxine hydrochloride (vitamin B6), in oral doses of 10 mg to 25 mg, may reverse the effects of levodopa by increasing the rate of aromatic amino acid decarboxylation." It adds that "carbidopa inhibits this action of pyridoxine," so the problem is plain levodopa — and 10 mg is enough to matter.
• Antiepileptic drugs, in both directions. Valproic acid, carbamazepine and phenytoin increase the breakdown of B6 vitamers, lowering plasma PLP. Going the other way, the NIH reports that "pyridoxine supplementation (200 mg/day for 12–120 days) can reduce serum concentrations of phenytoin and phenobarbital, possibly by increasing the drugs' metabolism" — a route to lost seizure control. Whether lower doses do this is not known.
• Cycloserine. This tuberculosis antibiotic increases urinary excretion of pyridoxine, and the loss "might exacerbate the seizures and neurotoxicity associated with cycloserine."
• Isoniazid. Competes with B6 metabolically, which is why supplementation is prescribed alongside it rather than added independently.
• Theophylline. Patients on it often have low plasma PLP, which may contribute to its neurological side effects, including seizures.
• Levetiracetam. Preliminary evidence suggests B6 at 50–100 mg/day in adults and 50–350 mg/day in children may reduce its behavioural side effects — doses above both ULs, which places them squarely in prescriber territory.

Pregnancy: where the 12 mg ceiling meets standard practice

This is the one place where the European limit and normal medical care openly diverge, and a pregnant reader deserves the explanation rather than a warning that contradicts her prescription.

EFSA's 12 mg/day applies during pregnancy and lactation. The FDA-approved delayed-release doxylamine–pyridoxine product for nausea and vomiting of pregnancy contains 10 mg of pyridoxine hydrochloride per tablet, with a starting dose of two tablets at bedtime and "a maximum recommended dose of four tablets daily" — that is 20 to 40 mg of B6 a day, two to more than three times the European ceiling.

There is no contradiction once you see what each number governs. The EFSA limit describes intakes people choose for themselves, indefinitely and without monitoring. The prescription describes a defined treatment for a defined problem, for a limited period, supervised by a clinician who has weighed the neuropathy risk against vomiting that can put a pregnancy at risk. What does not follow is buying a 50 mg tablet off the shelf and self-treating morning sickness with it.

How much B6 real food delivers

Per serving, from the NIH Office of Dietary Supplements (percentages are of the 1.7 mg FDA Daily Value):

Two corrections to the usual "top B6 foods" lists. The banana is a moderate source, not a standout: a cup of canned chickpeas carries nearly three times as much. And a single ordinary lunch does most of the day's work — a cup of chickpeas plus a banana is about 1.5 mg, above the 1.3 mg adult RDA before dinner. Adding up a day of real food is the fastest way to see whether a B6 supplement dose is filling a gap or just topping up a full tank.

Choosing a dose you can defend

1. Add up every source before choosing a number. Multivitamin, B-complex, energy drinks, meal-replacement shakes, fortified cereal. EFSA's 12 mg counts all of them together, and the extreme values in that market sit in fortified drinks rather than in pill bottles.
2. Do not assume a fancier form is a safer form. The EU authorises pyridoxine hydrochloride, pyridoxine 5'-phosphate and pyridoxal 5'-phosphate in supplements, and EFSA's limit explicitly "covers all vitamin B6 vitamers." There is no regulatory basis for treating P-5-P as exempt, so read the form and the milligrams on a B6 label rather than the claims on the front of the box.
3. Match the dose to a reason. For general nutrition the requirement is 1.3–2.0 mg and food probably covers it. For a specific condition, the doses used in trials were mostly not backed by strong evidence, and they belong in a conversation with a clinician who knows your medicines and your kidneys.

The single most useful takeaway from the numbers: the gap between "enough" (about 1.5 mg) and "documented harm in a national monitoring system" (21 mg in one case judged likely causal) is far narrower than the supplement aisle implies — and nothing in the trial evidence suggests the space between them is worth occupying.

References

1. Vitamin B6, Chapter 7 of Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline, Institute of Medicine (US), National Academies Press, 1998
2. Scientific opinion on the tolerable upper intake level for vitamin B6, EFSA Panel on Nutrition, Novel Foods and Food Allergens, EFSA Journal, 2023
3. Vitamin B6: Fact Sheet for Health Professionals, NIH Office of Dietary Supplements
4. Homocysteine-lowering interventions for preventing cardiovascular events, Martí-Carvajal et al., Cochrane Database of Systematic Reviews, 2017
5. The effect of vitamin B6 on cognition, Malouf and Grimley Evans, Cochrane Database of Systematic Reviews, 2003
6. Interventions for nausea and vomiting in early pregnancy, Matthews et al., Cochrane Database of Systematic Reviews, 2015
7. The effects of pyridoxine (vitamin B6) supplementation in nausea and vomiting during pregnancy: a systematic review and meta-analysis, Jayawardena et al., Archives of Gynecology and Obstetrics, 2023
8. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review, Wyatt et al., BMJ, 1999
9. Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome: a systematic review of randomized controlled trials, Robinson et al., Nutrition Reviews, 2025
10. High-dose vitamin B6 supplementation reduces anxiety and strengthens visual surround suppression, Field et al., Human Psychopharmacology: Clinical and Experimental, 2022
11. Long-term, supplemental, one-carbon metabolism-related vitamin B use in relation to lung cancer risk in the VITAL cohort, Brasky et al., Journal of Clinical Oncology, 2017
12. Plasma pyridoxal 5'-phosphate in the US population: NHANES 2003–2004, Morris et al., American Journal of Clinical Nutrition, 2008
13. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome, Schaumburg et al., New England Journal of Medicine, 1983
14. Characteristics of pyridoxine overdose neuropathy syndrome, Dalton and Dalton, Acta Neurologica Scandinavica, 1987
15. Daily Value on the Nutrition and Supplement Facts Labels, US Food and Drug Administration
16. Carbidopa and levodopa tablet, prescribing information, DailyMed, US National Library of Medicine
17. Isoniazid oral solution, prescribing information, DailyMed, US National Library of Medicine
18. Diclegis (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, prescribing information, DailyMed, US National Library of Medicine